Shamburg News · 8-K filed Nov 17, 2026, 4:41 PM EST
Protagenic Therapeutics Closes $1.5 Million Initial Closing of Private Placement of Common Stock and Warrants
PTIX · Protagenic Therapeutics, Inc.\new
- Material agreement
- Financing
- Materiality: high
On November 10, 2026, Protagenic Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement of 2,459,014 common shares and Series A and Series B common warrants at $0.61 per share and accompanying warrants. The initial closing occurred on November 17, 2026, with gross proceeds of approximately $1.5 million before placement agent fees and expenses, and additional closings may occur until December 31, 2026 with a maximum offering amount of $3,000,000. The securities were sold under Section 4(a)(2) and Rule 506(b) of Regulation D.
Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 7.01, 9.01, accession 0001493152-26-052871.
Written from the filing by Shamburg Markets. Figures are as reported by the company.